Rbc-Derived Mediators {#S1}
=====================

Export of Vasoactive Mediators by the Red Blood Cell (RBC) {#S1.SS1}
----------------------------------------------------------

The main job of the red blood cell is to load oxygen (O~2~) onto its hemoglobin (Hb) in the lung and deliver that O~2~ to respiring tissues throughout the body, while also facilitating the clearance of CO~2~ from tissues to lungs for exhalation into the environment. RBC Hb has evolved to serve these purposes smartly, for example fine-tuning the bias in O~2~ transport to respond to tissue needs by responding to allosteric effectors of Hb function such as pH and temperature. More recently, Hb has been recognized for its ability to export vascular mediators that regulate O~2~-sensitive blood in order to further optimize O~2~ delivery ([@B38]; [@B55]; [@B75]). For example, RBCs export a vasodilator S-nitrosothiol (SNO) group - pre-formed on Hb from nitric oxide (NO) -- in concert with the offloading of O~2~, endowing the RBC (blood) with the ability to flow preferentially where nutrient demand is greatest (as signaled by tissue hypoxia and transduced by the O~2~ sensor Hb itself). Here we review the export of such vasoactive mediators in the contexts of RBC deformation (which can also trigger mediator export) and RBC adhesive interactions with endothelial cells, which can be governed by such intercellular mediators.

Mechanisms of ATP Export by RBCs {#S1.SS2}
--------------------------------

Like other cells, RBCs depend on ATP for energy, and, lacking mitochondria, they generate this ATP via glycolysis. RBCs can export ATP in response to hypoxia or mechanical stress and lysis of ATP is not required for ATP liberation ([@B41]). RBCs do not have the capacity for regulated formation or extrusion of vesicles for extracellular export of molecules, although incidental formation of microparticles and nanoparticles derived from RBCs is well recognized ([@B9]). Therefore, the conduit for ATP export is likely to involve a channel, hemichannel, or pore. Evidence now suggests that the conduit for regulated export of ATP in response to some stimuli is the hemichannel pannexin 1 (a membrane protein analogous to innexins, an invertebrate homolog of the connexins that form gap junctions. Unlike pannexin, connexin molecules do not appear to be present in RBCs ([@B40]). Inhibitors or genetic ablation of pannexin 1 blocks the export of ATP in response to hypoxia and other stimuli, ([@B58]; [@B88]; [@B45]) but they did not appear to attenuate the release of ATP in response to hypotonic stress in the form of 75 mM potassium gluconate ([@B40]). However, regulated release of ATP may be difficult to assay reliably in the presence of hemolysis that is promoted by hypotonic conditions (see below). The mechanistic link between RBC deformation and ATP export has not been identified. However, recent work has indicated that the cell-volume response to deformation is mediated by the mechanosensor piezo1 calcium channel ([@B17]), and gain-of-function piezo1 mutation has been demonstrated in the RBCs of patients with xerocytosis ([@B85]; [@B5]). Whether piezo1 may participate in transducing RBC deformation-induced ATP release is unknown.

RBC Export of the NO Derivative SNO {#S1.SS3}
-----------------------------------

Red blood cells exploit allosteric transition cycles in hemoglobin (Hb) to support the production of S-nitrosothiols (SNOs) from nitric oxide (NO) and to drive the export from RBCs of SNOs ([@B75]). Specifically, deoxygenated or oxygenated human or rodent Hb binds NO avidly at its heme prosthetic groups. Upon transition to the oxygenated state, a redox reaction takes place and a reactive Cys (cysteine) residue in the beta chain (β93 Cys in human Hb) of Hb binds the NO equivalent (which now has NO + or nitrosonium character) ([@B38]; [@B55]). The SNO moiety thus formed in Hb can, as in other proteins, be transferred to a partner protein in a protein transnitrosylation reaction ([@B30]). For example, Hb can transfer its SNO moiety ([Figure 1](#F1){ref-type="fig"}) to a reactive Cys on RBC membrane resident band 3 (anion exchanger 1) ([@B63]). Deoxygenation drives Hb toward the T state, and allosterically this also promotes the release of SNO from Hb. Coincidentally, Hb-Band 3 interaction is also favored by RBC Hb deoxygenation. The route by which SNO leaves first the cytoplasmic domain of band 3 and then the RBC ([Figure 1](#F1){ref-type="fig"}) can involve the system L amino acid transporter (LAT) on RBC membranes, which efficiently transports CSNO ([@B25]). We recently identified a role for LAT1 in the export by RBCs of antiadhesive SNO. Whether deformation of the RBC can promote the export of SNO (as it promotes ATP export) is unknown. [Table 1](#T1){ref-type="table"} summarizes key actions and sites of action of exported and intracellular ATP and SNO.

![RBC deformation and export of vasoactive and antiadhesive mediators. Red blood cells sense and respond internally and externally to changing conditions as they traverse arterioles and capillaries. Specifically, RBCs deform and offload oxygen in progressively narrower and more hypoxic microvessels perfusing respiring tissues. The resulting RBC deformation and hemoglobin deoxygenation trigger the export of mediators like ATP and SNO that can regulate microvascular tone and prevent intercellular adhesion. This paracrine signaling enables the adaptive and unfettered flow of upstream RBCs as needed, and thereby optimizes O~2~ delivery and CO~2~ clearance. Responsible mediator transporters include pannexin 1 (P×1) for ATP and LAT1 (system L amino acid transporter) for SNO. RBC ATP and SNO can also act via autocrine mechanisms regulating functions including the RBC's ability to deform in response to shear stress.](fphys-10-01417-g001){#F1}

###### 

Targets and sites of action of ATP and SNO within and exported by RBCs.

  **ATP roles within the RBC**                                 **Proximal Source**                            **Target Cell**                                **Physiologic/pathologic Process**                                            **Method of assay**                                       **References**
  ------------------------------------------------------------ ---------------------------------------------- ---------------------------------------------- ----------------------------------------------------------------------------- --------------------------------------------------------- --------------------------------
  Support metabolic needs                                      EMP, PPP                                       RBC                                            ATP-requiring enzymes such as those for antioxidant defense                   HPLC/MS, luciferin/luciferase                             [@B67]
  Provide substrate for regulatory phosphorylation reactions   EMP, PPP                                       (RBC)                                          Regulation of solute transport, deformability                                 Phosphoproteomics, phosphoprotein-specific antibodies     [@B12]
  P2Y receptors: autocrine (negative feedback) G proteins      EMP, PPP                                       RBC surface                                    Feedback control of ATP export                                                ATP flux and receptor pharmacology and genetics           [@B84]
  **Roles of ATP exported by the RBC**                                                                                                                                                                                                                                                               
  P2X receptors                                                EMP, PPP                                       Leukocytes, endothelial cells                  PMN activation; PMN adhesion                                                  Receptor/ligand pharmacology                              [@B22]
  Unknown                                                      EMP, PPP                                       Endothelial cells                              Inhibition of RBC-EC adhesion                                                 n/a                                                       [@B88]
  Adenosine receptors after ectonucleotidase activity          ATP from EMP and PPP; ADO from ATPase action   Vascular smooth muscle cells; cardiomyocytes   Vasodilation; modulation of cardiac rhythm                                    Receptor/ligand pharmacology                              [@B16]
  **SNO roles within the RBC**                                                                                                                                                                                                                                                                       
  GAPDH: regulation of metabolism                              Undetermined                                   RBC                                            Metabolic regulation                                                          Biotin switch assay                                       [@B31]; [@B30]; [@B67]
  Spectrin and other cytoskeletal proteins                     Undetermined                                   RBC                                            Regulation of deformability; role in regulation of adhesion is undetermined   Biotin switch assay                                       [@B32]; [@B70]
  Hemoglobin                                                   Endothelial NO; eNOS in RBCs; NO~2~^--^        RBC                                            Allosteric coupling of RBC delivery of O~2~ and vasodilator SNO               MPC SNO assays; mouse genetics; SO~2~ gradient clamping   [@B38]; [@B55]; [@B49]; [@B20]
  AE1 (anion exchanger) aka Band 3                             Hb-bound SNO                                   RBC                                            Membrane-resident stationing of low-mass SNO for export by RBC                Pharmacologic probes                                      [@B63]
  Pannexin 1                                                   Undetermined                                   RBC                                            (S)NO regulation of ATP export                                                Biotin switch assay                                       [@B47]
  **Roles of SNO exported by the RBC**                                                                                                                                                                                                                                                               
  Soluble guanylate cyclase in vascular smooth muscle          RBC SNO                                        VSMC                                           RBC potentiation of hypoxic vasodilation                                      Pharmacologic inhibitors                                  [@B54]
  Platelet activation signaling elements                       RBC SNO                                        PLT                                            Inhibition of platelet aggregation                                            Platelet aggregometry                                     [@B65]
  Leukocyte adhesion receptors/ligands                         RBC SNO                                        WBC                                            Modulation of sickle RBC-driven leukocyte adhesion by NO/SNO                  Receptor/ligand antagonists                               [@B56]
  Endothelial adhesion receptors                               RBC SNO                                        EC                                             Modulation of RBC-EC adhesion                                                 Pharmacologic inhibitors                                  [@B25]

RBC Auto-Regulation of Exported SNO and ATP {#S1.SS4}
-------------------------------------------

In addition to their direct actions on endothelial cells and RBCs, RBC-derived ATP and NO/SNO can influence one another, an interaction which may serve to fine-tune the loop governing RBC of their (blood) flow. Specifically, ATP exported from RBCs stimulates eNOS in both the RBC itself and in endothelial cells, and the newly synthesized NO can inhibit further ATP export, possibly via S-nitrosylation of the ATP export channel pannexin 1 ([@B76]; [@B59], [@B60]; [@B47]; [@B81]). [@B76], [@B77] documented impaired ATP release from the RBCs of patients with idiopathic pulmonary arterial hypertension (IPAH, then called primary pulmonary hypertension (PPH). They suggested that the elevated PVR in these patients could be in part secondary to the expected decrease in pulmonary vascular NO synthase activity that results from diminished ATP flux in the pulmonary circulation. ATP can inhibit the activity of Px1, fine-tuning the level of extracellular (exported) ATP ([@B68]). This negative feedback effect appears to be mediated by the direct action of ATP on Px1 at extracellular sites bearing homology to P2 × 7 receptors.

Rbc Deformability and Deformation {#S2}
=================================

Investigation of RBC Deformability: Evolution of Methodology {#S2.SS1}
------------------------------------------------------------

The recent advent of more powerful techniques suitable for the study of single cells is accelerating our understanding of how deformability, mediators and adhesivity are linked. Notably, micropipette and filterability methods that allowed early single-cell study of RBC rheology ([@B18]) continue to yield insights. Various methods, differing in strengths and weaknesses, are available to investigators to evaluate RBC deformability. Ektacytometry uses the optical (laser) diffraction pattern to determine the change in length and width of a population of RBCs subjected to varying shear stresses. The commonly measured elongation index (EI) reports the change in length relative to the width as the RBC is stretched progressively by (typically incremental) shear stress. Alternatively, optical tweezer techniques are well suited in the current era of single-cell investigation. Optical force is applied to opposite ends of a visualized cell, and one of the laser beams is moved inward, deforming the cell. The degree of physical displacement of the cell in the perpendicular axis is determined visually. In a variation of the optical tweezers technique, both beams are directed at the cell, well within its boundaries, trapping the cell in place. Then one beam is slowly moved in a direction away from the other, stretching the cell. The degree of cellular narrowing (∼elongation again) is monitored. This approach was used to study the deformability of RBCs from type 2 diabetes mellitus (T2DM) patients with or without diabetic retinopathy in comparison to matched healthy controls ([@B1]). Deformability was modestly but significantly lower in both groups of T2DM patients than in the healthy controls. Notably, Skovburg and coworkers first reported on whole-blood viscosity elevation in diabetes at a time when diabetic RBCs had been reported to have normal viscosity ([@B74]). The single-cell approach and high resolution of this approach allowed the investigators also to document significant differences in the basal RBC length (∼diameter) and to show that deformability (expressed as the elongation index) was inversely related to RBC length. In addition to optical tweezers (or atomic force microscopy, AFM) and standard ektacytometer (e.g., laser-assisted optical red cell rotational analyzer, LORRCA), the ability of RBCs to pass through a filter ("RBC filterability") of a given size can be assessed as an index of deformability ([@B61]).

RBC Deformability, Deformation, and RBC Export of ATP in Health {#S2.SS2}
---------------------------------------------------------------

Red blood cells (RBCs) must be flexible, and they deform (e.g., elongate) in order to traverse capillaries efficiently. The ability of the discoid healthy RBC (and of RBCs in disease, when the shape may differ from discoid) to deform is a function of the instantaneous properties of the RBC cytoskeleton, the interactions of cytoskeleton with RBC membrane components (proteins and lipids), and the non-cytoskeletal properties of the cytosol, including the cellular hydration state and viscosity ([@B37]). The functional integrity of key cytoskeletal and membrane protein components such as spectrins (alpha and beta) and band 3 (anion exchanger 1; AE1), respectively, are in turn critically dependent on erythrocytic redox state and ATP levels. Cholesterol and other lipids of the RBC membrane play important regulatory functions in RBC deformability as well ([@B29]), in part via effects on fluidity and in turn viscosity. In this review, we discuss consequences of RBC deformation beyond the well-recognized direct implications for blood flow and RBC clearance. Specifically, RBCs sense the mechanical forces leading to deformation and respond by releasing vasoactive mediators that also influence blood flow by acting on the vascular endothelial or smooth muscle cells ([Figure 1](#F1){ref-type="fig"}). For example, ATP exported from deforming RBCs acts via purinergic receptors on endothelial cells to increase endothelial NOS activity. Thus, RBC deformation is an important stimulus for ATP export from RBCs and allows them to dilate arterioles and readily traverse capillaries that are in some cases smaller in diameter than the RBC itself. The degree to which hypoxia and deformation in the microcirculation lower intra-RBC ATP values is unknown, but it is unlikely that there is genuine ATP depletion (with adverse rheologic sequaleae) because extracellular ATP reaches a steady-state value ([@B58]; [@B40]) governed in part by the negative feedback mechanisms described at the end of Section I. [Figure 2](#F2){ref-type="fig"} illustrates the multiple cellular partners potentially influenced by RBC-derived ATP and SNO.

![SNO or ATP exported by RBCs can interact with various cell types to produce multiple beneficial or injurious responses in paracrine fashion. Extracellular roles played by RBC-derived SNO or ATP overlap partially. ATP or SNO efflux from vehicle RBCs can be salutary: vasodilation (green); or when preventing (red) adhesion or limiting (red) endothelial (EC) permeability. Note that SNO-induced vasodilation can be endothelium-independent, acting directly on vascular smooth muscle cells (VSMCs). Alternatively these mediators can be injurious, e.g., when acting as a DAMP (damage-associated molecular pattern). ATP can act as a DAMP by promoting (green) leukocyte (WBC) adhesion and activation, driving inflammation in acute lung injury. RBC-derived SNO may oppose WBC adhesion.](fphys-10-01417-g002){#F2}

Impaired RBC Deformability {#S2.SS3}
--------------------------

Impaired RBC deformability (as in RBC senescence, banking, or sickle cell disease) promotes the splenic sequestration of RBCs in narrow splenic sinusoids ([@B57]) and subsequently their clearance from circulation (extravascular hemolysis). Poorly deformable RBCs may also impede the flow of blood in other organs. Extravascular hemolytic clearance of RBCs can also be triggered by surface appearance ("externalization") of normally inward pointing phosphatidylserine (PS) ([@B13]), a component phospholipid of the membrane lipid bilayer. Other surface receptor or antigen changes can also trigger the splenic clearance of RBCs. Both impaired deformability and PS exposure can result from depression of ATP levels and may therefore represent pathways for the elimination from the circulation of metabolically incompetent RBCs.

Rbc-Derived Mediators and Endothelial Adhesion {#S3}
==============================================

Single-Cell Examination Suggests a Link Between RBC Adhesion and Deformability {#S3.SS1}
------------------------------------------------------------------------------

Interestingly, there is marked heterogeneity among sickle (SS) RBCs in terms of their deformability and adhesivity, even among the RBCs of a single individual person with sickle cell disease. [@B2] examined these properties using an innovative and physiologic microfluidic approach coupled with high-resolution imaging in whole blood samples that carry plasma proteins, which may participate in adhesive interactions. In addition to adhesion ligands on endothelial cells and in plasma, the extracellular matrix molecules fibronectin, laminin, and collagens may also bind to RBC surface adhesion molecules. The subset of mature sickle RBCs that are more deformable may paradoxically be the ones most likely to adhere. [@B62] examined the dynamics of the successive establishment of multiple sites of SS RBC adhesion to substrate (fibronectin, mimicking the vessel wall). Poorly deformable cells tended not to establish secondary foci of adhesion. Fewer sites of adhesion translates into weaker RBC-to-wall adhesion overall. The increased SS RBC adhesion measured in hypoxia appears to be secondary, at least in part, to the protrusion of HbS polymer fibers beyond the original cell boundary, increasing the cell surface area potentially available for adhesion. When mature sickle RBCs or sickle reticulocytes were reoxygenated, adhesion persisted, although the cellular protrusions typically receded.

RBC NO Derivatives, Deformability, and Adhesivity {#S3.SS2}
-------------------------------------------------

[@B70] investigated further the link between NO and the deformability and adhesivity of RBCs by examining under what conditions these properties can be corrected in RBCs deficient in Hb-bound NO. RBC banking for later transfusion leads to significant declines in S-nitrosohemoglobin (SNO-Hb) and to increased adhesivity and decreased deformability ([@B10]). The NO donor DEA/NO, which releases NO with a half-life of around 15 minutes, effectively promoted restoration of Hb-NO and SNO-Hb, particularly when the incubation was performed anaerobically ([@B70]). Anaerobic NO loading may optimize the loading of vacant heme groups within hemoglobin while avoiding oxidative side reactions as in the "methemoglobin (metHb) reaction" where nitrate and metHb are formed when NO and oxyhemoglobin react. As an alternative NO donor, PROLI NON-Oate was also effective, albeit with modestly lower yield relative to that from DEA/NO. Hb-NO yields are dose-dependent, and titration to levels measured in healthy fresh human RBCs led to partial correction of the changes in adhesivity and deformability arising from RBC storage in blood bank conditions. Several recent clinical trials have indicated that clinical outcomes in anemic patients receiving transfusion of RBCs stored for shorter than average periods (e.g., 7--10 days on average rather than 18 days) are not superior ([@B43]; [@B78]). However, marked changes take place *early* during RBC storage (for example in pH, glucose, and NO derivatives), and these changes universally present in all banked RBC units may limit the benefit of RBC transfusion. In fact, ill patients with any degree of anemia experience outcomes inferior to patients without anemia but matched for illness severity, ([@B34]) but whereas moderate correction of that anemia via RBC transfusion is beneficial, aggressive anemia correction is not beneficial ([@B34]; [@B44]; [@B51], [@B52]). This disconnect suggests that blood banked for any amount of time may function inferiorly to native blood, and that those storage lesions present early (arising in the first 7 days) may be important.

Identifying the Receptors/Ligands Mediating RBC Adhesion Sensitive to Exported Vasoactive ATP {#S3.SS3}
---------------------------------------------------------------------------------------------

The observation that RBC export of ATP from healthy human RBCs limits basal adhesion of the RBC raised the question of which RBC receptor, and/or which counterreceptor on the endothelial cell is normally inhibited by the continuously released ATP. Using antibodies to candidate adhesion receptors on both the RBC and the endothelial cell, the RBC LW (ICAM-4) and endothelial α~v~β~3~ integrin were identified as responsible ([@B88]). The mechanism by which exported ATP acts to limit endothelial adhesion is uncertain, but may involve the stimulation through purinergic receptors of NO production by eNOS in endothelial cells. ECs do produce NO in response to ATP, therefore RBC eNOS is not required ([@B15]). Beyond receptors and ligands, adhesivity has other determinants. Both RBC and EC surfaces include an external, carbohydrate-based glycocalyx coating. Important roles of the glycocalyx have been described recently, and one such function is to "mask" surface adhesion ligands in order to prevent unwanted adhesion events. The glycocalyx can also participate in transducing endothelial responses to shear stress ([@B53]; [@B23]). Additionally, the RBC surface is negatively charged, tending to repel circulating blood cells. The link, if any, between mediators exported by RBCs and these properties remains uncertain.

Rbc Mediators, Deformation, and Adhesion in Disease States {#S4}
==========================================================

Varying Timing of Blood Storage-Induced Changes in RBC Vasoregulatory and Antiadhesive Molecules {#S4.SS1}
------------------------------------------------------------------------------------------------

Conventional storage of RBCs is carried out using additive solutions designed to mitigate the loss of RBC organic phosphates including ATP and the critical allosteric effector diphosphoglycerate (aka 2,3-DPG, 2,3-BPG or simply "BPG"). The loss of ATP is slowed with the use of the additive solutions in current use, but BPG is nevertheless nearly absent by 14 days of storage. By comparison, shelf life is 35--42 days. Vasoactive NO derivatives in banked RBCs, by contrast, decline more rapidly, with hemoglobin-bound SNO and membrane SNO proteins markedly depressed by 3 h ([@B10]). The progressive loss of deformability of stored RBCs takes place over the order of weeks (like that of ATP and DPG) ([@B10]). [Table 2](#T2){ref-type="table"} summarizes representative changes in RBC deformability in several disease states or conditions, along with the associated changes in export of the mediators ATP and SNO and changes in RBC adhesivity to endothelial cells.

###### 

Changes in RBC deformability, adhesivity, and export of the vasoactive mediators ATP and S-nitrosothiols in sickle cell disease, RBC storage or transfusion, and sepsis.

                               **Disease or condition**                                                                                       
  ---------------------------- ----------------------------------------------------------- -------------------------------------------------- ----------------------------------------
  **RBC function**                                                                                                                            
  RBC deformability            ↓, especially when sickled ([@B2]; [@B37])                  ↓ progressive over weeks ([@B10]; [@B6])           ↓ ([@B66]; [@B7])
  ATP content ATP export       ↓ ([@B72]) ↓ (unpublished observations, TJM and M. Telen)   ↓ (both) progressive over weeks ([@B82]; [@B88])   ↓ ([@B8]; [@B48]) ↓ ([@B8]; [@B48])
  SNO content                  ↓ ([@B64])                                                  ↓ within hours ([@B10]; [@B69])                    **↑** ([@B39]; [@B21]; [@B46]; [@B24])
  SNO export or vasoactivity   ↓ ([@B64])                                                  **↓** within hours ([@B10]; [@B69])                **↑** ([@B21])
  RBC adhesivity               ↑ ([@B33]; [@B87])                                          ↑ ([@B4]; [@B88])                                  ↑ by LPS ([@B26])

Evolution of RBC "Storage Lesions" in Deformability and Adhesivity {#S4.SS2}
------------------------------------------------------------------

The longstanding question of whether anemic patients transfused with "older" RBC units benefit similarly to those receiving fresher RBC units has recently been addressed in a number of clinical settings. Clinical trials examining this issue were conducted in critically ill adults, cardiac surgery patients, neonates and others, and have used various ranges of storage time in the two study arms. In general, the evidence indicates that transfusion of older RBCs units, at least those in the age ranges employed in these trials, confers no excess harm. However, major changes take place within the first days or even hours of RBC storage. [@B11] demonstrated significant alterations of RBC shape, with the appearance of cells with globular echinocytic or otherwise abnormal shape as early as 5 days. These morphologic changes are accompanied by changes in the deformability of the RBCs and by hemolysis. pH in the RBC unit is below 7.0 in the first days of storage ([@B36]; [@B10]). Given these profound early changes, it is possible that even early changes in banked RBCs may have functional and clinical consequences, a scenario that is compatible with the lack of difference between clinical outcomes in patients given RBC units stored 1--2 weeks vs. units stored for over 2 weeks ([@B79]; [@B28]; [@B43]; [@B78]; [@B19]). Storage also promotes the adhesivity of RBCs, although the precise timing is not well defined ([@B4]; [@B10]).

Post-storage RBC Mediator Restoration {#S4.SS3}
-------------------------------------

Post-storage RBC mediator restoration can be accomplished when older RBCs are exposed to either renitrosylating (NO/SNO-restoring) or an ATP-repleting ("PIPA," containing phosphate, inosine, pyruvate, and adenine) solution. Indeed, several lines of evidence link NO derivatives with RBC deformability. Storage-induced changes in RBC deformability have been linked to post-transfusion recipient blood flow ([@B6]). Two structurally dissimilar NOS inhibitors, N^Ω^-nitro-L-arginine methyl ester and S-methylisothiourea, reduced human RBC deformability, effects that were reversible in the subsequent presence of the NO donors sodium nitroprusside (SNP) and diethylenetriamine (DETA)-NON-Oate ([@B14]). The rheologic effects of these NOS inhibitors suggested that RBCs may contain NOS, and evidence for an endothelial-type NOS in RBCs was demonstrated several years later ([@B42]). Post-storage renitrosylation of RBCs using DEA/NO led to augmented S-nitrosylation of beta-spectrin, a cytoskeletal protein critical for RBC deformation, and attenuated the storage-induced impairment in RBC deformability and the increased adhesivity ([@B70]). In mice transfused with RBCs renitrosylated using this strategy, the storage-induced RBC sequestration in the lung and associated impairment in blood oxygenation were ameliorated ([@B70]). It is unknown whether augmenting NO or its derivatives can also oppose excessive RBC adhesion in other diseases of the RBC, including sickle cell disease, malarial infection, and diabetes mellitus. Zennadi and colleagues reported that exposing deoxygenated sickle (SS, homozygous) RBCs to NO (followed by reoxygenation, promoting SNO-Hb formation) prevented the proadhesive effect of epinephrine. Hemoglobin-bound SNO is depressed in SS RBCs, and the deficiency tracks with disease severity ([@B64]). The impaired SNO formation may be secondary to a difference in the sickle Hb (HbS) heme's redox potential relative to that of HbA (the prevalent Hb type in normal adults).

RBC Mediators and Adhesion in Sickle Cell Disease {#S4.SS4}
-------------------------------------------------

Mechanistic investigation of the adhesion of activated sickle RBCs to endothelial cells (ECs), leukocytes, and platelets has yielded important insights into RBC adhesivity in general and therapeutically oriented leads in SCD in particular. Selectins on endothelial and white blood cells, and selectin receptors expressed on RBCs, participate in the "rolling" that characterizes initial contacts of leukocytes with the endothelium. Stronger and more durable intercellular attachment mediated by other ligand-receptor pairs follows but depends on the selectin system for initiation. Selective (anti-P-selectin) and non-specific selectin inhibitors have shown efficacy in phase two clinical trials and in one case a phase three trial. The stronger, secondary vascular adhesion of SS RBCs is mediated by several adhesion receptor/counterreceptor systems, including RBC ICAM-4 (also known as LW) that binds EC α~v~β~3~ integrin, RBC CD44 (hyaluronan receptor), and RBC BCAM/Lu which binds laminin. The reader is referred to excellent reviews specifically addressing mechanisms of RBC adhesion in sickle cell disease for a more comprehensive discussion of relevant adhesion ligands and receptors ([@B80]). The relative importance of these receptor/ligand systems varies depending in part on the adhesive stimulus. For example, elevated adhesivity in response to the stress hormone epinephrine acts through ICAM-4 activation with RBC binding to EC α~v~β~3~ integrin. Elements of the intracellular signaling pathways triggered by receptor activation have in some cases been identified and reveal an important node at which RBC ATP may govern adhesivity. Illustrating this is the role of G proteins, adenylate cyclase activation, elevation of cAMP, and the kinases MAPK and MEK in β2-adrenoceptor-mediated proadhesive signaling in response to epinephrine. It is unknown whether therapeutic manipulation of intra-RBC ATP can be leveraged to modulate kinase-dependent adhesion events, and the kinase-ATP link could also be considered in studies of organic phosphate manipulations in RBCs regardless of the primary mechanistic aim (whether targeting O~2~ affinity, ATP preservation for antioxidant defense, or when supplementing RBC ATP in order to boost ATP export capacity).

Modulation by Sickle RBCs of Endothelial Adhesion of Other Cells {#S4.SS5}
----------------------------------------------------------------

[@B86] demonstrated that human sickle (SS) RBCs activated by epinephrine and transfused into nude mice promote the adhesion of native peripheral blood mononuclear leukocytes (PBMCs) to endothelium. Adhesion receptors and counterreceptors on each cell type -- SS RBC, EC, and WBC -- were identified. RBCs can also inhibit the adhesion of other circulating cells: we demonstrated that the coincubation of fresh or 14-day-old healthy (AA) human RBCs with epi-activated SS RBCs attenuated their adhesivity, but that AA RBCs stored 30 days did not attenuate SS RBC adhesivity. The antiadhesive effect could be restored in 30-day-old RBCs by anaerobic NO loading (followed by reoxygenation) that also augmented RBC SNO (including Hb-bound SNO) content ([@B56]).

Adhesion and Deformability of RBCs in Thrombosis {#S4.SS6}
------------------------------------------------

RBCs form a substantial portion of venous thromboses, but their participation has been typically viewed as essentially passive. Disorders of the RBC membrane predispose to thrombosis, ([@B3]) and following the export from RBCs of ATP, endothelial and leukocytic ectonucleotidases can hydrolyze the ATP to proaggregatory ADP, ([@B35]) activating platelets and driving clot formation. It is conceivable that not all RBC adhesion is pathogenic. In addition to a homeostatic role in venous thrombosis, endothelial adhesion of RBC precursors may also play an important role in their homing in on supportive niches within the bone marrow microenvironment ([@B83]).

Mechanisms of RBC Clearance and Adhesion Can Overlap {#S4.SS7}
----------------------------------------------------

Cell surface ligands and receptors/counterreceptors mediating adhesion events overlap to some extent with those marking cells for clearance, and the RBC is no exception in this regard. Endothelial cells are competent for erythrophagocytosis, and RBC exposure to oxidative stress in response to tert-butyl hydroperoxide induced phosphatidylserine (PS) exposure, promoting subsequent erythrophagocytosis by ECs when opsonizing lactadherin was present ([@B27]), whether under static or flow conditions. Therefore PS exposure on RBCs, as occurs with RBC aging *in vivo* and in blood banking, promotes both endothelial adhesion and RBC clearance. RBC deformability was depressed in 10 patients with trauma-related sepsis ([@B66]); the mechanisms are as yet unidentified. The mechanistic study of RBC function in acute and subacute diseases is logistically and technically challenging. We recently described an improved technique for the cryopreservation of human RBCs, resulting in diminished RBC lysis after a cycle of controlled freezing in glycerol followed by thawing and deglycerolization ([@B71]), as compared to standard (clinical) RBC cryopreservation. The RBC phenotype with this approach matched closely that of aliquots from the same RBC samples studied before freezing and thawing. Superior cryopreservation is expected to enhance the ability of scientists to examine RBC structure, signaling and function at a time and place of their choosing and thus enable the collection and study of patients with disease states that cannot otherwise be practically investigated. For example, we are now utilizing this approach to collect and examine the molecular and functional basis for sepsis-induced red cell dysfunction.

Technical Note: Distinguishing Between Experimental Artifact (Hemolysis) and Genuine RBC Export of ATP or SNO in Response to Deformation or Hypoxia {#S4.SS8}
---------------------------------------------------------------------------------------------------------------------------------------------------

Modeling *in vitro* the hypoxia or deformation encountered by circulating RBCs in order to study the determinants and consequences of the export of vasoactive mediators such as SNO and ATP is challenging. Supraphysiologic levels of mechanical force, resulting either from poorly controlled deformation as the primary stimulus, or from inadvertent mechanical force of gases used to bubble RBC solutions to induce hypoxia, will unquestionably lead to cell rupture and the release of cellular contents (RBC lysis) including ATP. Importantly, the centrifugation used to separate the plasma or supernatant from treated RBCs can itself be sufficient to produce hemolysis, with liberation of ATP ([@B50]). We recommend gentle centrifugation for supernatant separation. When sample manipulation leads to both RBC lysis and ATP liberation, it is not surprising that the extent of hemolysis (% lysis, for example) will correlate numerically with the supernatant ATP concentration ([@B73]; [@B40]). Our approach to ensure scientific rigor and reproducibility in such experiments is to establish conditions in which RBCs can be made hypoxic with minimal mechanical perturbation. This establishes confidence that ATP release in hypoxia (for example) is non-lytic and actually a function of PO~2~ rather than of injurious mechanical force alone (as is sometimes used to "bubble" RBC preparations in order to deoxygenate). Additionally, we advise that in every experiment, the cell-free hemoglobin concentration be measured as an index of RBC lysis. We typically report the extent of hemolysis, and calculate to what extent the measured ATP~EC~ values could theoretically be secondary to the degree of lysis measured (taking into account the initial intra-RBC (ATP) and the hematocrit (Hct)\] ([@B88]; [@B71]). For example, if RBC \[ATP\] is 100 μM, experiment Hct is 1%, lysis of the RBCs is 5%, and the supernatant \[ATP\] is 100 nM, then ∼50% of the "ATP~EC~" could be from lysis. In this case, lysis is likely the primary driver of results. However, if under the same conditions lysis is measured at 1% (which alone would yield a supernatant \[ATP\] of 10 nM), then lysis alone may not account for inter-group differences. It is important to compare the degree of lysis (and the predicted ATP~EC~ resulting from that lysis) between experimental groups.

Perspective and Conclusion {#S5}
==========================

Deformation of RBCs is necessary for their flow and thus for cellular respiration, and not only promotes the physical passage of RBCs through microvessels, but also leads to the export of vasoactive and antiadhesive mediators, further optimizing flow as a function of need. These paracrine responses are analogous to the metabolically responsive and allosterically regulated export of vasoactive and antiadhesive ATP or SNO in response to RBC Hb deoxygenation. The deformation/mediator export/antiadhesive pathway is disturbed in pathology according to mechanisms that are still being identified. Primary or secondary defects in RBC deformability have the dual effect of directly impairing the ability of the RBC to flow freely through capillaries, and blunting the release of vasoactive mediators necessary for vasoregulation. Meanwhile, approaches to correcting such lesions or exploiting these delivery routes for broader therapeutic gain are being tested, informed by growing recognition of the molecular determinants of RBC mediator formation, release, and activity within the RBC and beyond.
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